Peng Hou

7.4k total citations
177 papers, 5.7k citations indexed

About

Peng Hou is a scholar working on Molecular Biology, Endocrinology, Diabetes and Metabolism and Oncology. According to data from OpenAlex, Peng Hou has authored 177 papers receiving a total of 5.7k indexed citations (citations by other indexed papers that have themselves been cited), including 120 papers in Molecular Biology, 40 papers in Endocrinology, Diabetes and Metabolism and 38 papers in Oncology. Recurrent topics in Peng Hou's work include Epigenetics and DNA Methylation (36 papers), Thyroid Cancer Diagnosis and Treatment (31 papers) and RNA modifications and cancer (30 papers). Peng Hou is often cited by papers focused on Epigenetics and DNA Methylation (36 papers), Thyroid Cancer Diagnosis and Treatment (31 papers) and RNA modifications and cancer (30 papers). Peng Hou collaborates with scholars based in China, United States and Netherlands. Peng Hou's co-authors include Meiju Ji, Mingzhao Xing, Qi Yang, Yiping Qu, Bingyin Shi, Haixia Guan, Dingxie Liu, Siwen Dang, Fang Sui and Adel K. El‐Naggar and has published in prestigious journals such as SHILAP Revista de lepidopterología, Nano Letters and ACS Nano.

In The Last Decade

Peng Hou

173 papers receiving 5.6k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Peng Hou 3.3k 1.6k 1.3k 1.1k 618 177 5.7k
Libero Santarpia 3.3k 1.0× 634 0.4× 1.8k 1.4× 2.2k 2.0× 773 1.3× 89 5.4k
Meiju Ji 2.1k 0.6× 1.1k 0.7× 784 0.6× 685 0.6× 388 0.6× 116 3.5k
Francesca Pentimalli 2.3k 0.7× 522 0.3× 1.1k 0.8× 922 0.8× 429 0.7× 120 3.8k
Joseph A. Fontana 3.8k 1.2× 659 0.4× 1.6k 1.3× 1.0k 0.9× 694 1.1× 144 6.0k
Joan M. Carboni 2.4k 0.7× 1.0k 0.6× 1.4k 1.1× 804 0.7× 361 0.6× 75 4.0k
Natasha Kyprianou 3.9k 1.2× 719 0.4× 2.0k 1.6× 1.7k 1.5× 2.7k 4.4× 135 7.5k
Junichi Kurebayashi 1.8k 0.5× 497 0.3× 1.9k 1.5× 999 0.9× 425 0.7× 157 3.8k
Ja Seung Koo 2.7k 0.8× 414 0.3× 2.4k 1.9× 2.8k 2.5× 807 1.3× 231 6.3k
Noboru Konishi 3.0k 0.9× 332 0.2× 1.4k 1.1× 1.2k 1.0× 1.2k 1.9× 239 6.3k
Yoon S. Cho‐Chung 4.1k 1.3× 394 0.2× 1.9k 1.5× 620 0.5× 464 0.8× 159 6.4k

Countries citing papers authored by Peng Hou

Since Specialization
Citations

This map shows the geographic impact of Peng Hou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peng Hou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peng Hou more than expected).

Fields of papers citing papers by Peng Hou

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peng Hou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peng Hou. The network helps show where Peng Hou may publish in the future.

Co-authorship network of co-authors of Peng Hou

This figure shows the co-authorship network connecting the top 25 collaborators of Peng Hou. A scholar is included among the top collaborators of Peng Hou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peng Hou. Peng Hou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Wang, Simeng, Jiaxin Liu, Pu Chen, et al.. (2025). Genome-wide CRISPR screening identifies PHF8 as an effective therapeutic target for KRAS- or BRAF-mutant colorectal cancers. Journal of Experimental & Clinical Cancer Research. 44(1). 70–70. 5 indexed citations
3.
Shi, Liang, Yan Liu, Xiang Ke, et al.. (2025). Disulfiram/copper triggers cGAS-STING innate immunity pathway via ROS-induced DNA damage that potentiates antitumor response to PD-1 checkpoint blockade. International Journal of Biological Sciences. 21(4). 1730–1748. 6 indexed citations
4.
Feng, Xiaoyu, Qing Chen, Yi Yang, et al.. (2025). CD34 in preeclampsia: The role of endothelial cell pyroptosis and regulation by melatonin via melatonin membrane receptor 1. International Journal of Biological Macromolecules. 318(Pt 4). 145188–145188.
5.
Wang, Jianling, et al.. (2025). Penfluridol enhances anti-tumor immunity in colorectal cancer by inducing proteasome-mediated degradation of PD-L1 via the activation of AMPK. Translational Oncology. 62. 102559–102559. 1 indexed citations
6.
Liu, Yan, et al.. (2024). USP44 inactivation accelerates the progression of thyroid cancer by inducing ubiquitylation and degradation of p21. International Journal of Biological Sciences. 20(13). 5223–5238. 1 indexed citations
7.
Chen, Quan, et al.. (2024). Engineering PD-L1 targeted liposomal canagliflozin achieves multimodal synergistic cancer therapy. Chemical Engineering Journal. 498. 155074–155074. 5 indexed citations
8.
Zhang, Rui, Yubo Wang, Mengdan Li, et al.. (2024). Targeting METTL3 enhances the chemosensitivity of non-small cell lung cancer cells by decreasing ABCC2 expression in an m6A-YTHDF1-dependent manner. International Journal of Biological Sciences. 20(12). 4750–4766. 7 indexed citations
9.
Zhou, Xinrui, et al.. (2023). Glucagon-modified Liposomes Delivering Thyroid Hormone for Anti-obesity Therapy. Archives of Medical Research. 54(4). 287–298. 4 indexed citations
10.
Yang, Qi, Hui Dang, Jiaxin Liu, et al.. (2023). Hypoxia switches TET1 from being tumor-suppressive to oncogenic. Oncogene. 42(20). 1634–1648. 13 indexed citations
11.
Liu, Juan, Xinru Li, Yubo Wang, et al.. (2023). Disulfiram/Cu Kills and Sensitizes BRAF-Mutant Thyroid Cancer Cells to BRAF Kinase Inhibitor by ROS-Dependently Relieving Feedback Activation of MAPK/ERK and PI3K/AKT Pathways. International Journal of Molecular Sciences. 24(4). 3418–3418. 18 indexed citations
12.
Qu, Yiping, et al.. (2021). Identification of a germline CSPG4 variation in a family with neurofibromatosis type 1-like phenotype. Cell Death and Disease. 12(8). 765–765. 2 indexed citations
13.
Su, Xi, Chao Feng, Simeng Wang, et al.. (2021). The noncoding RNAs SNORD50A and SNORD50B-mediated TRIM21-GMPS interaction promotes the growth of p53 wild-type breast cancers by degrading p53. Cell Death and Differentiation. 28(8). 2450–2464. 40 indexed citations
14.
Su, Xi, Zhen Shen, Qi Yang, et al.. (2019). Vitamin C kills thyroid cancer cells through ROS-dependent inhibition of MAPK/ERK and PI3K/AKT pathways via distinct mechanisms. Theranostics. 9(15). 4461–4473. 170 indexed citations
15.
Li, Yujun, Qi Yang, Haixia Guan, et al.. (2018). ZNF677 Suppresses Akt Phosphorylation and Tumorigenesis in Thyroid Cancer. Cancer Research. 78(18). 5216–5228. 53 indexed citations
16.
Sui, Fang, Xi Su, Pu Chen, et al.. (2018). Gender-related differences in the association between concomitant amplification of AIB1 and HER2 and clinical outcomes in glioma patients. Pathology - Research and Practice. 214(9). 1253–1259. 10 indexed citations
17.
Lv, Yanyan, Fang Sui, Jingjing Ma, et al.. (2016). Increased expression of EHF contributes to thyroid tumorigenesis through transcriptionally regulatingHER2andHER3. Oncotarget. 7(36). 57978–57990. 16 indexed citations
18.
Liu, Dingxie, Peng Hou, Zhi Liu, Guojun Wu, & Mingzhao Xing. (2009). Genetic Alterations in the Phosphoinositide 3-Kinase/Akt Signaling Pathway Confer Sensitivity of Thyroid Cancer Cells to Therapeutic Targeting of Akt and Mammalian Target of Rapamycin. Cancer Research. 69(18). 7311–7319. 75 indexed citations
19.
Hou, Peng, Ermal Bojdani, & Mingzhao Xing. (2009). Induction of Thyroid Gene Expression and Radioiodine Uptake in Thyroid Cancer Cells by Targeting Major Signaling Pathways. The Journal of Clinical Endocrinology & Metabolism. 95(2). 820–828. 112 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Libero Santarpia Breakdown of academic impact, for papers by Meiju Ji Breakdown of academic impact, for papers by Francesca Pentimalli Breakdown of academic impact, for papers by Joseph A. Fontana Breakdown of academic impact, for papers by Joan M. Carboni Breakdown of academic impact, for papers by Natasha Kyprianou Breakdown of academic impact, for papers by Junichi Kurebayashi Breakdown of academic impact, for papers by Ja Seung Koo Breakdown of academic impact, for papers by Noboru Konishi Breakdown of academic impact, for papers by Yoon S. Cho‐Chung
Rankless by CCL
2026